ZENTALIS PHARMACEUTICALS INC (ZNTL)

Company Profile

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The company is headquartered in San Diego, California and currently employs 168 full-time employees. The company went IPO on 2020-04-03. The firm is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The firm is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The firm is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.

Company Info

ZENTALIS PHARMACEUTICALS INC

10275 Science Center Drive, Suite 200

San Diego CALIFORNIA 10018

P: 18582634333

CEO: Anthony Y. Sun

Employees: 168

Website: https://www.zentalis.com/